Intrastriatal gene delivery of GDNF persistently attenuates methamphetamine self-administration and relapse in mice

International Journal of Neuropsychopharmacology

Volumn 16, Issue 7, 2013, Pages 1559-1567

  Yan, Yijin ^a,b   Miyamoto, Yoshiaki ^c   Nitta, Atsumi ^c   Muramatsu, Shin Ichi ^d   Ozawa, Keiya ^d   Yamada, Kiyofumi ^a   Nabeshima, Toshitaka ^a,e,f  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF TOYAMA   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e MEIJO UNIVERSITY   (Japan)

^f Japanese Drug Organization of Appropriate Use and Research   (Japan)

Author keywords

Adeno associated virus; cue induced reinstatement; gene therapy; glial cell line derived neurotrophic factor; methamphetamine; self administration

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ABUSE; DRUG DEPENDENCE; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; LOCOMOTION; MALE; MICROINJECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RELAPSE;

ANALYSIS OF VARIANCE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; CUES; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DRUG-SEEKING BEHAVIOR; ENVIRONMENT; EXTINCTION, PSYCHOLOGICAL; GENETIC THERAPY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GREEN FLUORESCENT PROTEINS; MALE; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; MICROINJECTIONS; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS;

EID: 84880521813     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712001575     Document Type: Article

References (31)

1. Chen YH, Harvey BK, Hoffman AF, Wang Y, Chiang YH, LuPoce CR (2008) MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector. FASEB J 22:261-275.
2. Choi-Lundberg DL, Lin Q, Chang YN, Chiang YL, Hay CM, Mohajeri H, Davidson BL, Bohn MC (1997) Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275:838-841.
3. Di Ciano P, Robbins TW, Everitt BJ (2008) Differential effects of nucleus accumbens core, shell, or dorsal striatal inactivations on the persistence, reacquisition, or reinstatement of responding for a drug-paired conditioned reinforcer. Neuropsychopharmacology 33:1413-1425.
4. Eberling JL, Kells AP, Pivirotto P, Beyer J, Bringas J, Federoff HJ, Forsayeth J, Bankiewicz KS (2009) Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in Parkinsonian rhesus monkeys. Hum Gene Ther 20:511-518.
5. Everitt BJ, Robbins TW (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8:1481-1489.
6. Franklin KBJ, Paxinos G (2007) The mouse brain in stereotaxic coordinates, 3rd edn. New York: Academic Press.
7. Green-Sadan T, Kinor N, Roth-Deri I, Geffen-Aricha R, Schindler CJ, Yadid G (2003) Transplantation of glial cell line-derived neurotrophic factor-expressing cells into the striatum and nucleus accumbens attenuates acquisition of cocaine self-administration in rats. Eur J Neurosci 18:2093-2098.
8. Green-Sadan T, Kuttner Y, Lublin-Tennenbaum T, Kinor N, Boguslavsky Y, Margel S, Yadid G (2005) Glial cell line-derived neurotrophic factor-conjugated nanoparticles suppress acquisition of cocaine self-administration in rats. Exp Neurol 194:97-105.
9. He DY, McGough NN, Ravindranathan A, Jeanblanc J, Logrip ML, Phamluong K, Janak PH, Ron D (2005) Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci 25:619-628.
10. Johnston LC, Eberling J, Pivirotto P, Hadaczek P, Federoff HJ, Forsayeth J, Bankiewicz KS (2009) Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther 20:497-510.
11. Kells AP, Eberling J, Su X, Pivirotto P, Bringas J, Hadaczek P, Narrow WC, Bowers WJ, Federoff HJ, Forsayeth J, Bankiewicz KS (2010) Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci 30:9567-9577.
12. Kirik D, Georgievska B, Bjorklund A (2004) Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci 7:105-110.
13. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, De'glon N, Aebischer P (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767-773.
14. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132.
15. Lu L, Wang X, Wu P, Xu C, Zhao M, Morales M, Harvey BK, Hoffer BJ, Shaham Y (2009) Role of ventral tegmental area glial cell line-derived neurotrophic factor in incubation of cocaine craving. Biol Psychiatry 66:137-145.
16. Mandel RJ, Spratt SK, Snyder RO, Leff SE (1997) Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 94:14083-14088.
17. Messer CJ, Eisch AJ, Carlezon JrWA, Whisler K, Shen L, Wolf DH, Westphal H, Collins F, Russell DS, Nestler EJ (2000) Role for GDNF in biochemical and behavioral adaptations to drugs of abuse. Neuron 26:247-257.
18. Miyazaki Y, Adachi H, Katsuno M, Minamiyama M, Jiang YM, Huang Z, Doi H, Matsumoto S, Kondo N, Iida M, Tohnai G, Tanaka F, Muramatsu S, Sobue G (2012) Viral delivery of miR-196a ameliorates the SBMA phenotype via silencing of CELF2. Nat Med 18:1136-1141.
19. Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, Kawakami T, Urabe M, Kume A, Sato T, Watanabe E, Ozawa K, Nakano I (2010) A phase I study of aromatic L-Amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 18:1731-1735.
20. Niwa M, Nitta A, Shen L, Noda Y, Nabeshima T (2007a) Involvement of glial cell line-derived neurotrophic factor in inhibitory effects of a hydrophobic dipeptide Leu-Ile on morphine-induced sensitization and rewarding effects. Behav Brain Res 179:167-171.
21. Niwa M, Nitta A, Yamada Y, Nakajima A, Saito K, Seishima M, Noda Y, Nabeshima T (2007b) An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha protects against methamphetamine-induced rewarding effects and sensitization. Biol Psychiatry 61:890-901.
22. Niwa M, Yan Y, Nabeshima T (2008) Genes and molecules that can potentiate or attenuate psychostimulant dependence : relevance of data from animal models to human addiction. Ann N Y Acad Sci 1141:76-95.
23. Pierce RC, Bari AA (2001) The role of neurotrophic factors in psychostimulant-induced behavioral and neuronal plasticity. Rev Neurosci 12:95-110.
24. Ron D, Janak PH (2005) GDNF and addiction. Rev Neurosci 16:277-285.
25. Su X, Kells AP, Huang EJ, Lee HS, Hadaczek P, Beyer J, Bringas J, Pivirotto P, Penticuff J, Eberling J, Federoff HJ, Forsayeth J, Bankiewicz KS (2009) Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and Parkinsonian rhesus monkeys. Hum Gene Ther 20:1627-1640.
26. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, Olson L (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335-339.
27. Wang L, Muramatsu S, Lu Y, Ikeguchi K, Fujimoto K, Okada T, Mizukami H, Hanazono Y, Kume A, Urano F, Ichinose H, Nagatsu T, Nakano I, Ozawa K (2002) Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther 9 :381-389.
28. Yan Y, Nabeshima T (2009) Mouse model of relapse to drugs of abuse: procedural considerations and characterizations. Behav Brain Res 196:1-10.
29. Yan Y, Nitta A, Mizoguchi H, Yamada K, Nabeshima T (2006) Relapse of methamphetamine-seeking behavior in C57BL/6J mice demonstrated by a reinstatement procedure involving intravenous self-administration. Behav Brain Res 168:137-143.
30. Yan Y, Yamada K, Nitta A, Nabeshima T (2007a) Transient drug-primed but persistent cue-induced reinstatement of extinguished methamphetamine-seeking behavior in mice. Behav Brain Res 177:261-268.
31. Yan Y, Yamada K, Niwa M, Nagai T, Nitta A, Nabeshima T (2007b) Enduring vulnerability to reinstatement of methamphetamine-seeking behavior in glial-cell-line-derived neurotrophic factor mutant mice. FASEB J 21:1994-2004.